Hydrazine → HCID 66780434, compound
Reaction equation
NN.[CH3:3][C:4]1[C:9]([C:10]([F:13])([F:12])[F:11])=[CH:8][CH:7]=[CH:6][C:5]=1[CH2:14][N:15]1[C:20]2[N:21]=[C:22]([N:24]3[CH2:29][CH2:28][O:27][CH2:26][CH2:25]3)[S:23][C:19]=2[C:18](=[O:30])[N:17]=[C:16]1[CH2:31][N:32]1C(=O)C2C(=CC=CC=2)C1=O>CO>[NH2:32][CH2:31][C:16]1[N:15]([CH2:14][C:5]2[CH:6]=[CH:7][CH:8]=[C:9]([C:10]([F:11])([F:13])[F:12])[C:4]=2[CH3:3])[C:20]2[N:21]=[C:22]([N:24]3[CH2:29][CH2:28][O:27][CH2:26][CH2:25]3)[S:23][C:19]=2[C:18](=[O:30])[N:17]=1Participants
4
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
Hydrazine (3.31 μL, 0.105 mmol) was added to a solution of 2-{[4-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-2-(4-morpholinyl)-7-oxo-4,7-dihydro[1,3]thiazolo[4,5-d]pyrimidin-5-yl]methyl}-1H-isoindole-1,3(2H)-dione (60 mg, 0.105 mmol) in Methanol (2 mL). The mixture was stirred at RT for 2 hours. The solvent was removed and the residue was purified by reverse phase HPLC (10% org˜50% org) to give the titled product 16 mg (35%). LC/MS (ES) m/z 440.1 (M+H)+, 1H NMR (400 MHz, DMSO-d6) δ ppm 8.30 (br, s, 2H), 7.67 (m, 1H), 7.38 (m, 1H), 6.87 (m, 1H), 5.58 (s, 2H), 4.20 (m, 2H), 3.66 (m, 4H), 3.56 (m, 4H), 2.37 (s, 3H)
Workup
- customThe solvent was removed
- customthe residue was purified by reverse phase HPLC (10% org˜50% org)
Sources & evidence
- ORD record
- ord-8b003ceb03724ceba47bcc0dbd090769
- Source dataset
- uspto-grants-2013_04
- Patent number
- US08410095B2
Reaction notes
Loading…